Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Yellow fever vaccine viremia following ablative BM suppression in AML

Bone Marrow Transplantation volume 48, pages 1008–1009 (2013)Cite this article

Subjects

Yellow fever vaccine (YFV) has been used for over 70 years in endemic areas. It is produced from 17D attenuated viral strain and is rarely associated with serious adverse events (SAE), such as anaphylaxis and YFV-associated neurotropic and viscerotropic diseases.1

Immunosuppressed patients and patients at extremes of age are at higher risk of developing YFV-associated adverse events (AE).1, 2 The vaccine is not recommended for infants less than six months old or for persons with altered immune status such as thymic disorders, AIDS and immunosuppressive therapies based on a presumed increased risk for YFV-associated SAE.3 YFV should be deferred in persons with a history of cancer or transplant recipients until immune recovery,4 as suggested by two reports describing the lack of YFV AE in immune-recovered BM recipients.5, 6

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26: 6077–6082.

    Article  CAS  Google Scholar 

  2. Kengsakul K, Sathirapongsasuti K, Punyagupta S . Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 2002; 85: 131–134.

    PubMed  Google Scholar 

  3. Centers for Disease Control and Prevention. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010; 59: 32.

    Google Scholar 

  4. Pickering LK, Baker CJ, Freed GL, Gall SA, Grogg SE, Poland GA et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 817–840.

    Article  Google Scholar 

  5. Gowda R, Cartwright K, Bremner JA, Green ST . Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol 2004; 72: 299–301.

    Article  CAS  Google Scholar 

  6. Yax JA, Farnon EC, Cary Engleberg N . Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow fever vaccine. J Travel Med 2009; 16: 365–367.

    Article  Google Scholar 

  7. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J . Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56: 159–167.

    Article  CAS  Google Scholar 

  8. Niedrig M, Lademann M, Emmerich P, Lafrenz M . Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999; 4: 867–871.

    Article  CAS  Google Scholar 

  9. Nascimento Silva JR, Camacho LA, Siqueira MM, Siqueira MM, Freire Mde S, Castro YP et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29: 6327–6334.

    Article  Google Scholar 

  10. National Institute for Biological Standards and Control. WHO reference reagent. The 1st international reference preparation for anti-yellow fever serum monkey. Available from http://www.nibsc.ac.uk/documents/ifu/YF.pdf, 2008 (accessed March 15, 2011.

  11. Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 2008; 151: 40–46.

    Article  CAS  Google Scholar 

  12. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T . The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 2012; 86: 359–372.

    Article  Google Scholar 

  13. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358: 98–104.

    Article  CAS  Google Scholar 

  14. Galler R, Pugachev KV, Santos CL, Ocran SW, Jabor AV, Rodrigues SG et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001; 290: 309–319.

    Article  CAS  Google Scholar 

  15. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD . Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358: 121–122.

    Article  CAS  Google Scholar 

  16. Engel AR, Vasconcelos PF, McArthur MA, Barrett AD . Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006; 24: 2803–2809.

    Article  CAS  Google Scholar 

  17. Bae HG, Domingo C, Tenorio A, de Ory F, Muñoz J, Weber P et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008; 197: 1577–1584.

    Article  Google Scholar 

  18. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008; 198: 500–507.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious and Parasitic Diseases, University of Sao Paulo Medical School, Sao Paulo, Brazil

    V I Avelino-Silva, F E Leal, E C Sabino & E G Kallas

  2. Hospital Sirio-Libanes, Sao Paulo, Brazil

    V I Avelino-Silva, F E Leal, F Blumm, V Rocha, C A Rodrigues, Y S Novis & E G Kallas

  3. Division of Clinic Immunology and Allergy, University of Sao Paulo Medical School, Sao Paulo, Brazil

    F E Leal & E G Kallas

  4. Fundação Pro-Sangue Hemocentro de São Paulo, São Paulo, Brazil

    E C Sabino & A S Nishiya

  5. Infectious Diseases Division (DIPA), Federal University of São Paulo, São Paulo, Brazil

    A S Nishiya

  6. Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

    M da Silva Freire

Authors
  1. V I Avelino-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F E Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E C Sabino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A S Nishiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M da Silva Freire
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Blumm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C A Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y S Novis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E G Kallas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V I Avelino-Silva.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Avelino-Silva, V., Leal, F., Sabino, E. et al. Yellow fever vaccine viremia following ablative BM suppression in AML. Bone Marrow Transplant 48, 1008–1009 (2013). https://doi.org/10.1038/bmt.2012.277

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.277

This article is cited by

Search

Advanced search

Quick links